Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1308A + Lenvatinib in 1L Advanced Hepatocellular Carcinoma
NCT04740307Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2021
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of quavonlimab in hepatocellular carcinoma (HCC), sponsored by Merck & Co.. Started Mar 2021; status: completed.
02
Drugs
quavonlimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04740307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04740307.